Business
PRTC’s Seaport: GlyphAllo Paper Published
PureTech Health plc announced that its Founded Entity, Seaport Therapeutics, has published first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300) in Science Translational Medicine, demonstrating it as the first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans. The publication details the Glyph platform's ability to enable oral dosing and supports the ongoing Phase 2b clinical trial of GlyphAllo for major depressive disorder. Phase 1 trials showed GlyphAllo was generally well-tolerated and provided therapeutically relevant allopregnanolone plasma exposures, while a Phase 2a trial demonstrated a significant reduction in salivary cortisol versus placebo (p=0.0001) after a single 375 mg dose. The Glyph platform's broad applicability beyond neuropsychiatry is also highlighted. Disclaimer*
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n25 March 2026\nPureTech Health plc\n \n PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAlloTM (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the publication of first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300 or Glyph Allopregnanolone) in Science Translational Medicine.\n \nThe GlyphAllo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company's strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech's Founded Entity, Seaport Therapeutics.\n \nThe full text of the announcement from Seaport is as follows:\n \nSeaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAlloTM (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans\n \nNewly published findings further support clinical validation of Seaport's proprietary Glyph™ platform to enable oral dosing\n \nData supported advancement of ongoing Phase 2b clinical trial of GlyphAllo in major depressive disorder (MDD)\n \nBOSTON, March 25, 2026 - Seaport Therapeutics (\"Seaport\" or the \"Company\"), a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders with a proven strategy and team, today announced the first comprehensive disclosure of first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300 or Glyph Allopregnanolone), a novel, Glyphed oral prodrug of allopregnanolone, published in Science Translational Medicine, tracing the program's pathway from discovery through initial proof-of-concept. The peer-reviewed article, t...